Top Markets
#1 TENDIES TENDIES +42.62%
#2 Cash Cat Cash Cat +27.92%
#3 ICON ICON +23.59%
#4 Asteroid Shiba Asteroid Shiba +17.29%
#5 OSK OSK +15.36%
#6 MarsCoin MarsCoin +13.78%
#7 Threshold Network Threshold Network +12.29%
#8 龙虾 (Lobster) 龙虾 (Lobster) +10.00%
#9 Tornado Cash Tornado Cash +9.69%
#10 Kite Kite +9.57%
Coin of the day
TENDIES TENDIES
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Classificação em ações #16410
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Preço da ação
$3.12
Última sincronização: 2026-09-01
Valor de mercado
$294.21M
Variação (1 dia)
-3.26%
Variação (1 ano)
-54.86%
País
US
Negociar Myriad Genetics, Inc. (MYGN)

Categoria

Healthcare
Histórico de desdobramentos de ações de Myriad Genetics, Inc. (MYGN)
As ações Myriad Genetics, Inc. (símbolo: MYGN) passaram por um total de 0 desdobramentos.
O desdobramento mais recente ocorreu em Sep 02, 2026.
Uma ação MYGN comprada antes de Sep 02, 2026 equivaleria hoje a 0 ações MYGN.
Lista de desdobramentos de ações
Ano Desdobramento Multiplicador Multiplicador cumulativo
Não há dados suficientes para as datas fornecidas.
Desdobramentos de ações de empresas semelhantes ou concorrentes
Empresa Número de desdobramentos de ações Multiplicador cumulativo País
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 8 x34
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 7 x47
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 0 -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 0 -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 4 x15
US